MedTrace Logo

Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease

NCT06750575 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2024-12-27

No results posted yet for this study

Summary

The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). The main question it aims to answer is: what is the effect of furosemide on plasma levels of PBUTs in patients with CKD? Besides, the investigators will also look at the effect of furosemide on the excretion of PBUTs via the urine.

Participants will be included in the study once they will be prescribed furosemide as part of routine patient care. Before they start with the furosemide treatment, patients will undergo the following:

* Blood pressure measurement
* Blood sample withdrawal
* Urine sample collection
* 12-hour urine collection

Then, one to four weeks after starting with furosemide treatment, patients will undergo the following:

* Blood pressure measurement
* Blood sample prior to furosemide intake (Tmin)
* Blood sample withdrawal 90 minutes after furosemide intake (Tmax: time at which the highest furosemide plasma level is expected)
* Urine sample collection 60-120 minutes after furosemide intake
* 12-hour urine collection

The investigators expect furosemide to increase plasma levels of PBUTs by decreasing the renal excretion of the toxins.

Conditions

  • Chronic Kidney Diseases
  • Renal Failure Chronic

Interventions

DIAGNOSTIC_TEST

Invasive measurements

Blood and urine samples will be collected during the study.

Sponsors & Collaborators

  • Maastricht University, MERLN Institute for Technology-Inspired Regenerative Medicine

    collaborator UNKNOWN

  • Utrecht Institute for Pharmaceutical Sciences

    collaborator OTHER

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Karin GF Gerritsen, MD, PhD · UMC Utrecht

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06750575 on ClinicalTrials.gov